Previous 10 | Next 10 |
Fiscal 2019 Fourth Quarter Highlights Net sales of $96.3 million, an increase of 9.0% year over year and 5.2% organically Gross margin of 53.6%, flat year-over-year GAAP EPS of $1.54 per share; adjusted EPS of $0.25 per share Completed sale of NAMIC Fluid Managem...
ANGO , MSM For Seeking Alpha's full earnings season calendar, click here . More news on: AngioDynamics, Inc., MSC Industrial Direct Co., Inc., Earnings news and commentary,
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2019 before the market open on ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the Raymond James Life Scienc...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC ® fluid management portfolio to Medline Ind...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that representatives of the Company will ring the NASDAQ Stock Market closing bell on Tuesday, May 28, 2019...
The FDA has signed off on AngioDynamics' ( ANGO -1% ) application to launch a pilot study evaluating its NanoKnife Irreversible Electroporation for the ablation of prostate cancer tissue in low-risk patients. More news on: AngioDynamics, Inc., Healthcare stocks news, Read more ... ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational dev...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced enrollment of the first patient in its NanoKnife ® Irreversible Electroporation (IRE) “ D at...
Quick Take Varian ( VAR ) announced it has acquired CyberHeart for an undisclosed amount. CyberHeart has intellectual property that covers cardiac radioablation - the use of radiation to scar or destroy tissue in the heart that is facilitating faulty electrical signals, causing an abnorm...
News, Short Squeeze, Breakout and More Instantly...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is schedule...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...